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Long-Term Prognosis of Patients Diagnosed With
Brugada Syndrome
Results From the FINGER Brugada Syndrome Registry
V. Probst, MD, PhD*; C. Veltmann, MD*; L. Eckardt, MD*; P.G. Meregalli, MD*; F. Gaita, MD;
H.L. Tan, MD, PhD; D. Babuty, MD, PhD; F. Sacher, MD; C. Giustetto, MD;
E. Schulze-Bahr, MD, PhD; M. Borggrefe, MD, PhD; M. Haissaguerre, MD; P. Mabo, MD, PhD;
H. Le Marec, MD, PhD; C. Wolpert, MD, PhD; A.A.M. Wilde, MD, PhD
Background—Brugada syndrome is characterized by ST-segment elevation in the right precordial leads and an increased
risk of sudden cardiac death (SCD). Fundamental questions remain on the best strategy for assessing the real
disease-associated arrhythmic risk, especially in asymptomatic patients. The aim of the present study was to evaluate
the prognosis and risk factors of SCD in Brugada syndrome patients in the FINGER (France, Italy, Netherlands,
Germany) Brugada syndrome registry.
Methods and Results—Patients were recruited in 11 tertiary centers in 4 European countries. Inclusion criteria consisted
of a type 1 ECG present either at baseline or after drug challenge, after exclusion of diseases that mimic Brugada
syndrome. The registry included 1029 consecutive individuals (745 men; 72%) with a median age of 45 (35 to 55) years.
Diagnosis was based on (1) aborted SCD (6%); (2) syncope, otherwise unexplained (30%); and (3) asymptomatic
patients (64%). During a median follow-up of 31.9 (14 to 54.4) months, 51 cardiac events (5%) occurred (44 patients
experienced appropriate implantable cardioverter-defibrillator shocks, and 7 died suddenly). The cardiac event rate per
year was 7.7% in patients with aborted SCD, 1.9% in patients with syncope, and 0.5% in asymptomatic patients.
Symptoms and spontaneous type 1 ECG were predictors of arrhythmic events, whereas gender, familial history of SCD,
inducibility of ventricular tachyarrhythmias during electrophysiological study, and the presence of an SCN5A mutation
were not predictive of arrhythmic events.
Conclusions—In the largest series of Brugada syndrome patients thus far, event rates in asymptomatic patients were low.
Inducibility of ventricular tachyarrhythmia and family history of SCD were not predictors of cardiac events. (Circulation.
2010;121:635-643.)
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B rugada syndrome (BrS) is an arrhythmogenic diseasecharacterized by a typical ECG pattern of ST-segment
elevation in the right precordial leads and an increased risk of
sudden cardiac death (SCD) due to ventricular fibrillation.1
Clinical Perspective on p 643
Patients displaying the BrS ECG pattern were initially
considered at high risk of SCD, but recent studies have
demonstrated that at least asymptomatic patients have a low
risk of arrhythmic events.2–5 Risk stratification and therapeu-
tic approach in asymptomatic patients are still controversial.
The second consensus report on BrS, published in 2005,
considered an electrophysiological study (EPS) as the corner-
stone of the therapeutic strategy.6,7 EPS was described as a
valuable stratification tool in asymptomatic patients, and, if
positive, implantation of an implantable cardioverter-
defibrillator (ICD) was recommended (class II recommenda-
tion).7 Several other studies, however, have failed to identify
the inducibility of ventricular tachyarrhythmias as a predictor
for SCD.2–5
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The aim of the present study was to evaluate the prognosis
and risk factors of SCD in BrS patients in the FINGER
(France, Italy, Netherlands, Germany) Brugada registry.
Methods
Consecutive patients were included at the following university
hospitals: Academic Medical Centre, Amsterdam (n5159) (Nether-
lands); University of Muenster (n577) and University Hospital of
Mannheim (n580) (Germany); Cardinal Massaia Hospital of Asti,
University of Torino (n5192) (Italy); and the reference center for
arrhythmic diseases in Nantes (n5521) (France), which includes
patients from the university hospitals of Bordeaux, Brest, Rennes,
Tours, Angers, Poitiers, Strasbourg, and Nantes (France). This
international registry also contains follow-up data on patients in-
cluded in a previous study published in 2005 and recently reported
Italian patients.2,8
From the present study comprising 1029 patients, 212 patients
were initially described in Circulation in 2005.2 The follow-up of
this population was 40650 months. These patients represent most of
the population included in the registry before 2003. In this popula-
tion of 305 individuals, we obtained a follow-up of 69 months. The
Italian group included 192 patients in the registry; of them, 166 have
also been described in Europace.8
Finally, 378 of the 1029 patients have already been included in a
publication, which means that 657 patients are new. We can consider
that over a total follow-up of 1029337538 073 months, the patients
from the Eckardt publication represent 21234058480 months of
follow-up, and the patients from the Europace publication from the
Italian group represent 16633054980 months, for a total of 13 460
months. Finally, the FINGER registry presents 24 613 new months
of follow-up. Only patients displaying a type 1 ECG at baseline or
after provocation with a class I antiarrhythmic drug and at least 1
follow-up visit available were included (Figure 1). Children younger
than 16 years were excluded.
Clinical data of interest were (1) age, (2) gender, (3) circumstances
at diagnosis, and (4) family history of SCD. All of the ECGs were
reviewed and classified by expert cardiologists (A.A.M.W., V.P.,
L.E., C.W., F.G.). BrS diagnosis was made according to the criteria
of the consensus report.7,9 Intravenous ajmaline or flecainide was
used for class I drug challenge. Routine examinations, including at
least echocardiography, excluded any underlying structural heart
disease, and laboratory tests excluded acute ischemia and metabolic
or electrolyte abnormalities.
Three groups were classified according to the circumstances under
which the ECG abnormalities were documented: subjects after an
episode of aborted SCD, subjects during diagnostic evaluation of
syncope (considered to be probably of arrhythmic origin), and
asymptomatic subjects who had a type 1 or a suspicious ECG (type
2 or 3) during routine examination or who underwent family
screening. Typical different types of ECG are presented in Figure 1.
The classification as spontaneous type 1 ECG or drug-induced type
1 ECG was made with regard to the ECG pattern at the time of the
diagnosis. The patient group was defined at the time of inclusion in
the registry.
EPS was performed in 638 patients. A maximum of 3 ventricular
extrastimuli was delivered from 2 ventricular sites. In case of
ventricular fibrillation induced with a minimum coupling interval of
,200 ms for the last extrastimuli, the EPS was considered negative.2
Patients were treated on the basis of the clinical judgment of the
participating centers. During follow-up, patients were considered to
have an arrhythmic event if SCD occurred, or, if appropriate, ICD
shocks or sustained ventricular tachyarrhythmias were documented.
Mutation analysis of the SCN5A gene followed standard accepted
protocols for genetic testing and is described elsewhere.2,10
Statistical Analysis
Data were analyzed with the SPSS and SAS packages (SPSS Inc,
Chicago, Ill; SAS Institute Inc, Cary, NC), We used the x2 or Fisher
exact test to compare categorical variables. The Mann-Whitney and
Kruskal-Wallis tests were performed to test for statistical differences
in continuous parameters. The mean event rate per year was
evaluated by the number of events occurring during the follow-up
divided by the number of patients multiplied by the average duration
of follow-up. Continuous data are presented as median and inter-
quartile range. Time from ECG diagnosis to the first event was
analyzed with the Cox proportional hazards model. Hazard ratios
(HR) and confidence intervals (CI) are presented in univariate
analysis and only with significant P values in multivariable
analysis. Survival curves were plotted by the Kaplan–Meier
method. Multivariable analysis was performed with the following
variables: gender, age, type of symptoms, type 1 ECG, inducibil-
ity of ventricular tachyarrhythmias during EPS, and ICD implan-
tation (at the baseline time point). A value of P,0.05 was
considered statistically significant.
Results
Patient Population
The registry included 1029 consecutive individuals (745 men;
72%) with a median age of 45 (35 to 55) years at diagnosis
(female 49 [36 to 57] versus male 44 [35 to 55] years;
P50.03); 808 individuals (78%) were index patients (Table).
The circumstances of diagnosis were as follows: (1) aborted
SCD in 62 patients (6%); (2) syncope in 313 (30%); and (3)
lack of symptoms in 654 (64%). Of these, 239 (36.5%) were
Figure 1. Typical representation of type
1, type 2, and type 3 ECGs. Only type 1
is diagnostic for BrS.
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identified during family screening, 21 during an ECG per-
formed for palpitation (3.2%), 12 during presyncope (1.8%),
and 382 (58.4%) after a routine ECG.
Overall, a spontaneous type 1 ECG was recorded in 468
patients (45%): 31 subjects (50%) from the cardiac arrest
group, 169 (54%) from the syncope group, and 268 (41%)
from the asymptomatic group (P50.001). Median ST-
segment elevation in leads V1 through V3, at baseline, was 2
(0.4 to 3) mm in the cardiac arrest group, 2 (1 to 4) mm in the
syncope group, and 2 (0.3 to 3) mm in the asymptomatic
group (P50.002). In the asymptomatic group, a spontaneous
type 1 ECG was found in 45 (19%) of the patients diagnosed
during a family screening and in 223 other patients (54%)
(P,0.001). We identified a type I ECG limited to the third
intercostal space in 43 of 1029 patients.
EPS was performed in 638 individuals (62%). In 262
patients (41%), sustained ventricular tachyarrhythmias were
inducible. The rate of inducible ventricular tachyarrhythmia
was higher in previously symptomatic patients (125/269) than
in asymptomatic individuals (137/369) (46% versus 37%;
P50.02).
Among 516 index patients in whom genetic analysis was
performed, an SCN5A mutation was found in 115 (22%). In
70 (52%) of the 134 screened family members, an SCN5A
mutation was found.
Treatment
ICD implantation was performed in 54 of 62 patients from the
cardiac arrest group (87%), in 208 of 313 syncope group
patients (66%), and in 171 of 654 asymptomatic patients
(26%). An ICD was implanted in 118 of 137 (86%) of the
asymptomatic patients with a positive EPS.
The ICD implantation rate was higher in symptomatic than
in asymptomatic patients (69.9% versus 26.1%; P,0.001).
Eight patients from the cardiac arrest group did not undergo
ICD implantation because of severe brain damage.
Eight patients were treated with hydroquinidine; 3 of them
were diagnosed after aborted SCD, 2 were diagnosed after
syncope, and 3 were asymptomatic.
Follow-Up Data
The median follow-up period for the entire study population
was 31.9 (14 to 54.4) months. Follow-up was significantly
longer in the cardiac arrest group patients (44 [26 to 68]
months) than in the syncope group (34 [14 to 58] months) or
the asymptomatic group (31 [13 to 53] months; P50.003).
During follow-up, 51 arrhythmic events occurred: appropriate
ICD shocks (44 patients) and SCD (7 patients). The mean
event rate per year for the entire population was 1.6%. Seven
patients died from noncardiac causes (Figure 2).
During follow-up, 22 of 62 patients (35%) from the cardiac
arrest group, 19 of 313 patients (6%) from the syncope group,
and 10 of 654 (1.5%) patients from the asymptomatic group
had an arrhythmic event. The mean event rates per year were
7.7%, 1.9%, and 0.5%.
Univariate Analysis
Symptoms
Time to first event was shorter in the cardiac arrest group
patients than in the asymptomatic group patients (HR, 12.4;
CI, 5.6 to 27.3; P,0.001). Furthermore, time to first event
was shorter in the syncope group patients than in the
asymptomatic group patients (HR, 3.4; CI, 1.6 to 7.4;
P50.002) (Figure 3).
In the asymptomatic group, there was no difference in the
time to first event between patients diagnosed during familial
screening and patients diagnosed during other circumstances
(HR, 0.7; CI, 0.2 to 2.8; P50.63).
ECG Pattern at Time of Diagnosis
Patients with a spontaneous type 1 ECG had a shorter time to
first arrhythmic event than patients in whom the type 1 ECG
Table. Patient Characteristics According to Their Clinical Presentation
Cardiac Arrest Group Syncope Group Asymptomatic Group P
No. of patients 62 313 654
Index patients, % 98 93 70 ,0.001
Male, n (%) 55 (89) 238 (76) 452 (69) 0.01
Age at diagnosis, y 43 (35–54) 46 (37–57) 45 (35–55) 0.19
Family history of SCD, n (%) 6 (10) 63 (20) 195 (30) ,0.001
PR, ms 160 (130–190) 180 (158–200) 171 (160–195) 0.01
QRS, ms 106 (95–120) 105 (93–117) 100 (92–115) 0.19
ST elevation, mm 2 (0.4–3) 2 (1–4) 2 (0.2–3) 0.002
Spontaneous type 1 ECG, n (%) 31 (50) 169 (54) 268 (41) 0.001
EPS performed, n (%) 36 (58) 233 (74) 369 (56) ,0.001
Inducible VT/VF, n (%) 16 (44) 109 (47) 137 (37) 0.06
SCN5A mutations, n (%) 12/49 (24) 53/203 (26) 120/398 (30) 0.92
Follow-up,* mo 44 (26–68) 34 (14–58) 31 (13–53) 0.01
No. of patients with events during follow-up 22 19 10 ,0.001
Mean event rate per year, % 7.7 1.9 0.5
VT/VF indicates ventricular tachycardia/ventricular fibrillation.
*The follow-up is the time between the first event or the last new date and the diagnosis ECG date.
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was shown only during drug challenge (mean event rate per
year, 2.3% versus 1.07%; HR, 2.1; CI, 1.2 to 3.6; P50.01)
(Figure 4).
Gender
Male gender tended to be associated with a shorter time to
first event, but this difference did not reach statistical signif-
icance (mean event rate per year, 3.0% for men versus 0.9%
for women; HR, 1.9; CI, 0.9 to 4.2; P50.08).
Genetic Data
There was no difference in time to first event between SCN5A
mutation carriers and noncarriers (HR, 1.1; CI, 0.5 to 2.2;
P50.8).
Figure 2. Mean event rate per year during follow-up in the entire population. The results are divided according to the type of ECG and
the presence of symptoms. Results of EPS are also given in the different groups. FU indicates mean follow-up in months in the group.
Figure 3. Kaplan–Meier curves of arrhythmic events during follow-up in the 3 different groups. Patients from the cardiac arrest group
(n562) had a shorter time to ﬁrst arrhythmic event than patients from the asymptomatic group (n5654), and patients from the syncope
group (n5313) had a shorter time to ﬁrst arrhythmic event than patients from the asymptomatic group.
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Family History of SCD
Overall, a family history of SCD at a young age (,45 years)
was found in 264 patients (26%). This information was not
available for 12 patients (1%). The event rates per year did
not differ between patients with a family history of SCD and
those without (1.29% versus 1.7%). A family history of SCD
was not predictive of arrhythmic events in either the group of
symptomatic or the group of asymptomatic patients (symp-
tomatic patients, 3.3% versus 3.0%; asymptomatic patients,
0.5% versus 0.6%).
Electrophysiological Study
At univariate analysis, patients with inducible ventricular
tachyarrhythmias (n5262; 41%) had a significantly shorter
time to first arrhythmic event than patients with a negative
EPS (n5376; 59%) (mean event rates per year, 2.3% versus
1.2%; HR, 1.9; CI, 0.9 to 3.9; P50.05; Figure 5).
Multivariable Analysis
In a multivariable analysis, symptoms before inclusion
(P,0.001), SCD versus asymptomatic status (HR, 11; CI, 4.8
to 24.3; P,0.001), syncope versus asymptomatic status (HR,
3.4; CI, 1.6 to 7.4; P50.002), and spontaneous type 1 ECG
versus drug-induced type 1 ECG (HR, 1.8; CI, 1.03 to 3.33;
P50.04) were predictors of a shorter time to first arrhythmic
event. The results of the EPS (P50.48), age (P50.27), and
gender (P50.60) were not predictive of a shorter time to first
arrhythmic event, however.
If introduced in the multivariable analysis, ICD implanta-
tion (HR, 3.9; CI, 1.4 to 10.6; P50.007) was found to be a
predictor of a shorter time to first arrhythmic event.
Asymptomatic Patients
A separate analysis was performed in asymptomatic patients.
Neither spontaneous type 1 ECG (event rate per year, 0.8%
versus 0.4%; HR, 2.0; CI, 0.5 to 7.4; P50.26) nor male
gender (0.7% versus 0.2%; HR, 3.0; CI, 0.3 to 22; P50.35)
nor age (HR, 0.9; CI, 0.3 to 3.3; P50.92) was predictive of a
shorter time to the first arrhythmic event during follow-up.
Results of EPS were available in 369 asymptomatic indi-
viduals. In univariate analysis, patients with positive EPS
(n5137; 37%) had a shorter time to first arrhythmic event
compared with those with a negative EPS (n5232; 63%;
event rate per year, 1.1% versus 0.4%; HR, 5.2; CI, 1 to 25.8;
P50.05). The multivariable analysis, restricted to the asymp-
tomatic patients, showed no independent predictive value:
EPS (P50.09), male gender (P50.42), spontaneous type 1
ECG (P50.38), and age (P50.97).
If introduced in the multivariable analysis, ICD implanta-
tion (HR, 10.1; CI, 1.7 to 58.7; P50.01) was found to be a
predictor of a shorter time to first arrhythmic event.
Analysis of Patients Diagnosed Before 2003
In 305 patients, the diagnosis was performed before 2003. In
this subpopulation, the average follow-up was 66 (56 to 82)
months. During follow-up, 34 arrhythmic events occurred
(event rate per year, 1.9%): 15 of 31 cardiac arrest group
patients (48%), 11 of 101 syncope group patients (11%), and
8 of 173 asymptomatic group patients (4.5%) had an arrhyth-
mic event. Thus, the event rates per year were 7.4%, 1.8%,
and 0.8%, respectively (Figure 6).
Figure 4. Kaplan–Meier curves of arrhythmic events during follow-up depending on the ECG pattern. Patients displaying a spontaneous
type 1 ECG (n5468) had a shorter time to ﬁrst arrhythmic event than patients in whom the type 1 ECG was induced after challenge
with sodium channel blockers (n5561); P50.01.
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Discussion
The aim of this study was to evaluate the prognosis and assess
the value of clinical and electrophysiological parameters for
risk stratification in a large series of individuals with either a
spontaneous or drug-induced type 1 Brugada ECG. The study
population consisted of 1029 individuals from 4 different
European countries, who were included in the FINGER
Brugada syndrome registry. A large group of these patients
underwent ICD implantation because of primary or secondary
prevention. One of the major characteristics of this population
is that patients have been consecutively enrolled in defined
geographic regions within the 4 European countries. This
registry was built as a result of an exhaustive recruitment of
the available clinical data of all of the BrS patients of these
areas and, as such, is representative of daily practice in
clinical cardiology. Therefore, in contrast to previous studies
Figure 5. Kaplan–Meier curves of arrhythmic events during follow-up depending on the results of the EPS. Patients in whom EPS
induced ventricular ﬁbrillation (n5262) had a shorter time to the ﬁrst arrhythmic event than those with a negative EPS (n5376); P50.05.
Figure 6. Mean event rate per year during follow-up, restricted to the group of patients recruited in the database before 2003. Results
are divided according to the type of ECG and the presence of symptoms. FU indicates mean follow-up in months in the group.
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based on worldwide registries, which were potentially subject
to a referral bias with inclusion of more severely affected
subjects, the present findings may more accurately reflect
disease severity.
Since the BrS was identified in 1992, major progress has
been made in understanding the pathophysiology of the
disease and in identifying its genetic basis.1,10–19 The diag-
nostic workup and the therapeutic approach to BrS have been
described extensively in 2 comprehensive consensus re-
ports.7,9 Nevertheless, controversy still exists regarding the
role of EPS for risk stratification and the manner in which to
proceed with asymptomatic patients.2,5,20–22 In the last con-
sensus report, EPS was offered to patients exhibiting a
spontaneous type 1 ECG or patients with a type 1 ECG
revealed by drug challenge but with a positive family history
of SCD (class II-b).7 This approach involves performing a
large number of EPS, which in turn leads to a high number of
ICD implantations. This not only may result in a considerable
increase in healthcare costs but also may expose asymptom-
atic individuals to ICD-related complications.23
Overall, the incidence of arrhythmic events in asymptom-
atic patients in the FINGER registry is low: SCD occurred in
2 (0.4%) of 478 asymptomatic patients in whom an ICD was
not implanted. The event rate in asymptomatic patients was
0.5% per year.
Given the low event rate overall, it remains difficult to
recommend a suitable therapeutic approach for asymptomatic
patients. In multivariable analysis, no predictor for cardiac
events could be identified. A risk of 0.5% per year for a
period of 40 years (mean life expectancy of a patient
diagnosed with BrS) leads to a potential cumulative risk of up
to 20%. If this calculation were true, then ICD implantation
should be recommended; however, it is currently impossible
to estimate the evolution of arrhythmic risk over time in
patients with BrS.
To answer this question, we performed a subanalysis of the
subjects who were registered before 2003. The event rate per
year in this subpopulation was 0.8% in asymptomatic pa-
tients, which is similar to the rate of 0.5% found in the entire
asymptomatic patient population. Does this mean that the risk
of arrhythmic events occurring in this population remains
stable over time? Probably not, because it must be noted that
in our registry the median age at the time of an arrhythmic
event (45 [38 to 57] years) was close to the age of diagnosis
(45614 [35 to 55] years). Thus, even if one extends
follow-up from 3 to 6 years, the follow-up period remains
close to the peak of event period of time, which may lead to
an overestimation of event risk.24
In the FINGER Brugada registry, the arrhythmic end point
was defined as appropriate ICD shock or SCD. Most of the
events were appropriate ICD shocks (86%), and only 7 SCDs
occurred. This high incidence of appropriate shocks must be
taken into account when the results are interpreted. Because
ventricular tachyarrhythmias may terminate spontaneously,
appropriate ICD shock is not synonymous with SCD.25,26 The
storage of all ventricular tachycardias (exceeding the monitor
zone of the device but still possibly asymptomatic) in patients
with an ICD leads to an overestimation of the number of
events compared with patients without an ICD. The predic-
tive value of the EPS is difficult to assess because its positive
result will most frequently lead to ICD implantation (236/262
patients in the FINGER registry; 90%), whereas a signifi-
cantly smaller proportion of asymptomatic patients with a
negative EPS underwent ICD implantation (102/376 patients;
27%; P,0.0001). Accordingly, the positive predictive value
of EPS was found only at univariate analysis and was not
confirmed by multivariable analysis, whereas the presence of
an ICD was found to be predictive of the occurrence of
arrhythmic events. This could certainly explain in part the
discrepancy between the different registries.2,5,27
Until now, the only available treatment that has proven to
prevent SCD in BrS patients is ICD implantation.5,28 This
intervention represents an attractive option to protect patients
against SCD. It has been shown recently, however, that the
incidence of ICD-related complications is high in this popu-
lation (up to 28%), and death related to ICD malfunction has
also been reported.23,29,30
Clearly, the risk/benefit ratio of ICD implantation in this
population is not easy to assess. Therefore, an open discus-
sion with the patient explaining the potential risks of the
disease but also the possible complications of the ICD is a
crucial point. Quinidine therapy may be an alternative in
patients refusing the ICD or ineligible for ICD implantation,
although available data are limited and future prospectively
designed studies are needed.31–35
Limitations
Even if the follow-up of this study is the longest published
thus far, because patients are usually diagnosed in the fifth
decade of life, this follow-up is still too short to draw final
conclusions. Risk stratification in the present study is based
on 1 basal ECG, whereas fluctuation of the ST-segment
elevation over time is a well-demonstrated feature of the
syndrome.36 In all of the published multicenter studies, 1
ECG is used for risk assessment. Not all of the asymptomatic
patients underwent an EPS, and therefore a selection bias
cannot be completely excluded. Although the number of
patients included here is large, the number of asymptomatic
patients who underwent EPS is actually relatively small. All
of the patients younger than 16 years were excluded from the
registry, and therefore no comment can be made on BrS in
children in this registry.
Conclusions
The present study demonstrates that, in the largest cohort of
patients with BrS thus far, the risk of arrhythmic events is low
in asymptomatic patients (event rate per year, 0.5%). The
presence of symptoms and a spontaneous type 1 ECG are the
only independent predictors of arrhythmic events. Con-
versely, gender, family history of SCD, inducibility of ven-
tricular tachyarrhythmias during EPS, and presence of a
mutation in the SCN5A gene have no predictive value. In
view of these results, a revision of the therapeutic strategy
proposed in the second consensus report is warranted.
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CLINICAL PERSPECTIVE
Brugada syndrome is characterized by ST-segment elevation in the right precordial leads and an increased risk of sudden
cardiac death. Fundamental questions remain on the best strategy for assessing the real disease-associated arrhythmic risk,
especially in asymptomatic patients. The aim of the present study was to evaluate the prognosis and risk factors of sudden
cardiac death in Brugada syndrome patients in the FINGER (France, Italy, Netherlands, Germany) Brugada syndrome
registry. The registry included 1029 consecutive individuals (72% men). In the registry, 36% of the patients were
symptomatic, and 64% were asymptomatic. The cardiac event rate per year was 7.7% in patients with aborted sudden
cardiac death, 1.9% in patients with syncope, and 0.5% in asymptomatic patients. Symptoms and spontaneous type 1 ECG
were predictors of arrhythmic events, whereas gender, familial history of sudden cardiac death, inducibility of ventricular
tachyarrhythmias during electrophysiological study, and the presence of an SCN5A mutation were not predictive of
arrhythmic events. In the FINGER registry, the rate of cardiac events in the asymptomatic Brugada syndrome patients was
low, and the inducibility of ventricular tachyarrhythmias during electrophysiological study did not properly stratify the
arrhythmic risk.
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